LEO Pharma and Research Project BIOMAP: Towards Personalised Medicine for Inflammatory Skin Diseases
The large-scale IMI project will investigate the causes and mechanisms of Atopic Dermatitis and Psoriasis
BALLERUP, Denmark, April 11, 2019 – LEO Pharma, a global leader in medical dermatology and BIOMAP, a EU-funded research project (Biomarkers in Atopic Dermatitis and Psoriasis), today announced that BIOMAP kicks off its activities with the aim of improving the lives of patients affected by the two most common inflammatory skin conditions. Addressing key unmet needs in treating atopic dermatitis and psoriasis by analysing data from more than 50,000 patients, the five-year project will have a broad impact on disease understanding, patient care and future therapies. In addition to LEO Pharma the team comprises 26 academic and five industry partners as well as five patient organisations. The European Innovative Medicines Initiative (IMI) and the participating pharma companies provide EUR 20.8 million funding for the first IMI project in the field of dermatology.
Atopic dermatitis and psoriasis affect more than 300 million people worldwide and are highly variable in terms of onset, severity, progression over time and response to treatment. Resulting in significant morbidity and an increased risk for associated conditions such as arthritis and asthma, inflammatory skin diseases are a huge burden to patients and families, care-givers and healthcare systems. Yet, despite many years of research, there are still significant gaps in the understanding of both conditions.
The renowned clinicians and scientists of BIOMAP, who have now joined forces in a large public-private partnership, will examine the causes and mechanisms of these conditions. By analysing the largest collection of patient data ever and performing advanced molecular investigations at the single cell level and in the tissue context, they aim at identifying biomarkers for variations in disease outcome. Taking advantage of recent technical developments in translational medicine, the project will drive drug discovery and improve direct disease management by combining clinical, genetic and epidemiological expertise with modern molecular analysis techniques and newly-developed tools in bioinformatics. BIOMAP is the first IMI project in the field of dermatology.
“BIOMAP will help us to better understand the relationships between inherited susceptibility, environmental factors, and molecular profiles, as well as the roles of each of these in onset and progression of the diseases”, says Dr Witte Koopmann, industrial co-project lead from LEO Pharma.
Professor Stephan Weidinger, academic coordinator of the consortium and internationally-renowned clinician scientist from the University of Kiel Germany, hopes that “atopic dermatitis and psoriasis will be identified as a series of different diseases rather than just one disease, each with a characteristic molecular ‘signature’.”
“The findings from BIOMAP will drive rapid drug discovery to target causal mechanisms, and will pinpoint biomarkers which can support clinicians to decide who, when and how to intervene”, expects BIOMAP’s academic co-coordinator Professor Catherine Smith from King’s College London.
The voices of patients living with Atopic Dermatitis and Psoriasis will be at the heart of BIOMAP, through the establishment of a Patient Advisory Group. It will ensure that patients’ insights, opinions and wishes are taken into account across all the multiple components of the project.
BIOMAP is funded by the Innovative Medicines Initiative 2 Joint Undertaking under Grant Agreement No. 821511 and in-kind contributions of the participating pharma companies. The Joint Undertaking receives support from the European Union’s Horizon 2020 research and innovation programme and EFPIA.
The project will officially kick off its activities with a first meeting in London on 10-12 April, 2019.
EURICE – European Research and Project Office GmbH
Dr Verena Peuser
Phone +49 30 374415832
LEO Pharma A/S
Trine Juul Wengel
Tel.: +45 20732037
About LEO Pharma
The Innovative Medicines Initiative (IMI) is Europe’s largest public-private initiative aiming to improve health by speeding up the development of, and patient access to, innovative medicines, particularly in areas where there is an unmet medical or social need. IMI facilitates collaboration between the key players involved in healthcare research, including universities, the pharmaceutical and other industries, small and medium-sized enterprises (SMEs), patient organisations, and medicines regulators. It is a partnership between the European Union (represented by the European Commission) and the European pharmaceutical industry (represented by EFPIA, the European Federation of Pharmaceutical Industries and Associations). For further information: www.imi.europa.eu
About LEO Pharma
LEO Pharma helps people achieve healthy skin. The company is a leader in medical dermatology with a robust R&D pipeline, a wide range of therapies and a pioneering spirit. Founded in 1908 and owned by the LEO Foundation, LEO Pharma has devoted decades of research and development to advance the science of dermatology, setting new standards of care for people with skin conditions. LEO Pharma is headquartered in Denmark with a global team of 5,500 people, serving 76 million patients in 130 countries. In 2018, the company generated net sales of DKK 10,410 million.
For more information, go to: www.linkedin.com/company/leo-pharma or www.leo-pharma.com
Subscribe to releases from LEO Pharma
Subscribe to all the latest releases from LEO Pharma by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from LEO Pharma
LEO Pharma announces positive top-line results for tralokinumab from three Phase 3 studies in adult patients with moderate-to-severe AD11.12.2019 08:05:00 CET | Press release
BALLERUP, Denmark, December 11, 2019 – LEO Pharma A/S, a global leader in medical dermatology, today announced that tralokinumab – an investigational, fully human monoclonal antibody that specifically neutralizes the interleukin-13 (IL-13) cytokine – met all primary and secondary endpoints in its three pivotal Phase 3 studies (ECZTRA 1-3) for the treatment of moderate-to-severe atopic dermatitis (AD) in adults. During the studies, the overall adverse event rate was comparable between tralokinumab and placebo. IL-13 is a key driver of the type 2 inflammation that plays a major role in AD,(1) which is the most common inflammatory skin disease in the developed world,(2) affecting up to five percent of adults across the United States, Canada, Europe and Japan.(3) AD can have a significant, negative impact on patients’ well-being, primarily due to distressing itch, sleep deprivation and social stigmatization due to visible lesions.(4) “In its moderate-to-severe form, AD can cause unbearable
LEO Pharma and Portal Instruments Announce Collaboration to Develop Needle-Free Drug Delivery Device4.12.2019 09:03:00 CET | Press release
Ballerup, DENMARK and Cambridge, MA, USA – December 4, 2019 – LEO Pharma A/S and Portal Instruments today announced a global collaboration and license agreement to develop Portal’s innovative needle-free drug delivery system for use in combination with LEO Pharma’s portfolio of investigational and approved medicines.
Birgitta Stymne Göransson elected member of LEO Pharma’s Board of Directors14.11.2019 09:04:51 CET | Press release
BALLERUP, Denmark, November 14, 2019 – LEO Pharma A/S today announced that Birgitta Stymne Göransson has been elected member of the company’s Board of Directors.
LEO Pharma exercises option with HitGen to license compounds for development of novel class of drugs in dermatology12.11.2019 08:00:00 CET | Press release
Ballerup, DENMARK and Chengdu, CHINA, November 12, 2019 – LEO Pharma A/S and HitGen Inc. are pleased to announce that HitGen and LEO Pharma expands their collaboration with a license to develop a novel class of drugs for a dermatology indication.
LEO Pharma enters into option agreement with Ubiquigent for access to novel compounds30.10.2019 08:00:00 CET | Press release
Ballerup, DENMARK and Dundee, UNITED KINGDOM, 30 October 2019 - Ubiquigent Limited (Ubiquigent) and LEO Pharma A/S announced today that they have entered into an option agreement granting LEO Pharma access to two novel compounds. Today’s announcement follows on from an earlier agreement between the parties entered into as part of LEO Pharma Open Innovation. Under the terms of this latest agreement LEO Pharma will pay Ubiquigent an upfront fee, followed by a further fee on exercise of the option and potential downstream milestone payments. LEO Pharma and Ubiquigent entered into an agreement in 2018, as part of LEO Pharma Open Innovation, with the objective of evaluating a collection of Ubiquigent’s novel compounds across LEO Pharma’s in-house disease-relevant assays. This approach identified a number of active compounds, two of which will now be subject to the agreement announced today. Ubiquigent’s Managing Director, Mr. Jason Mundin commented, “LEO Pharma Open Innovation has been an e
Ny offentligt/privat samarbejde sætter fokus på udnyttelse af patienters viden til medicinudvikling29.10.2019 10:58:52 CET | Pressemeddelelse
Patienter er dem, der ved mest om deres egen sygdom. Hvordan kan deres viden udnyttes til at fremstille bedre medicin? Det er filosofien og motivationen for et nyt, forskningsbaseret offentligt-privat samarbejde, som sætter fokus på potentiale og barrierer for brugerinddragelse i forbindelse med udvikling af ny medicin.
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.Visit our pressroom